Rubicon Research started its market journey with a big splash! The company’s shares listed on October 16, 2025, at ₹620 per share, giving investors a solid 28% premium over the IPO price of ₹485. This debut proved that investor confidence in the pharma and healthcare sector remains strong. 👉 Source: Moneycontrol
rubicon research share price
IPO Details and Investor Response
Price Band: ₹461 – ₹485 per share
Total Subscription: The IPO was subscribed 48 times, showing strong retail and institutional demand.
The response was driven by the company’s R&D strength and U.S. export exposure.
Listing Day Highlights
NSE Listing Price: ₹620
BSE Listing Price: ₹620.10 Both exchanges saw an impressive opening, delivering quick gains to investors.
Grey Market Premium (GMP) & Expectations
Before listing, Rubicon Research shares were trading with a GMP of nearly 30%, and the actual listing premium came
close to expectations. This shows that the company had strong market buzz before debut.
Financial Performance & Future Plans
According to Business Today, Rubicon Research’s operating income tripled, and EBITDA grew six-fold in the last three financial years (FY22–FY25). The company plans to use IPO proceeds for loan repayment, business expansion, and acquisitions in the pharma development space.
Risks to Watch
A large portion of revenue comes from the U.S. market, which could face regulatory and geopolitical challenges.
Global competition in pharmaceutical research remains high.
Investor’s View
Analysts believe Rubicon Research is a promising growth story, but investors should wait for consistent quarterly performance before long-term investment.
⚠️ Disclaimer
All data in this post are verified from trusted financial sources (Moneycontrol, Business Today, Economic Times). Prices mentioned are based on 16 October 2025 listing day. Always check real-time stock data on NSE/BSE websites or apps like Groww, Zerodha, or Angel One before investing.
